MX2023007641A - Derivados de 4-amino-3-(4-fenoxifenilo)-1,3-dihidro-2h-imidazo[4,5 -c]piridin-2-ona y sales de los mismos. - Google Patents
Derivados de 4-amino-3-(4-fenoxifenilo)-1,3-dihidro-2h-imidazo[4,5 -c]piridin-2-ona y sales de los mismos.Info
- Publication number
- MX2023007641A MX2023007641A MX2023007641A MX2023007641A MX2023007641A MX 2023007641 A MX2023007641 A MX 2023007641A MX 2023007641 A MX2023007641 A MX 2023007641A MX 2023007641 A MX2023007641 A MX 2023007641A MX 2023007641 A MX2023007641 A MX 2023007641A
- Authority
- MX
- Mexico
- Prior art keywords
- phenoxyphenyl
- imidazo
- dihydro
- derivatives
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130010P | 2020-12-23 | 2020-12-23 | |
| US202163245288P | 2021-09-17 | 2021-09-17 | |
| PCT/US2021/064800 WO2022140511A1 (en) | 2020-12-23 | 2021-12-22 | 4-amino-3-(4-phenoxyphenyl)-1,3- dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007641A true MX2023007641A (es) | 2023-07-07 |
Family
ID=79730613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007641A MX2023007641A (es) | 2020-12-23 | 2021-12-22 | Derivados de 4-amino-3-(4-fenoxifenilo)-1,3-dihidro-2h-imidazo[4,5 -c]piridin-2-ona y sales de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12624030B2 (enExample) |
| EP (1) | EP4267572A1 (enExample) |
| JP (1) | JP2024501247A (enExample) |
| KR (1) | KR20230124663A (enExample) |
| CN (1) | CN116710452B (enExample) |
| AU (1) | AU2021409575B2 (enExample) |
| CA (1) | CA3206176A1 (enExample) |
| CO (1) | CO2023009491A2 (enExample) |
| IL (1) | IL303834A (enExample) |
| MX (1) | MX2023007641A (enExample) |
| TW (1) | TW202241887A (enExample) |
| WO (1) | WO2022140511A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3168146A1 (en) | 2020-01-20 | 2021-07-29 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms) |
| CA3201936A1 (en) | 2020-12-10 | 2022-06-16 | Minhua Chen | Crystal form of tolebrutinib and preparation method thereof |
| IL303834A (en) | 2020-12-23 | 2023-08-01 | Genzyme Corp | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts |
| EP4540229A1 (en) * | 2022-06-14 | 2025-04-23 | Principia Biopharma Inc. | Methods of making tolebrutinib |
| US20260022123A1 (en) * | 2022-06-22 | 2026-01-22 | Principia Biopharma Inc. | Methods of Making Modified BTK Inhibitors |
| AU2024214470A1 (en) | 2023-02-01 | 2025-09-11 | Principia Biopharma Inc. | Methods of diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3760984A (en) | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
| US3952741A (en) | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
| WO2003037890A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Piperidines |
| CA2485641C (en) | 2002-06-06 | 2010-12-14 | Eisai Co., Ltd. | Novel condensed imidazole derivatives |
| US20060045822A1 (en) | 2004-09-01 | 2006-03-02 | Board Of Regents, The University Of Texas System | Plasma polymerization for encapsulating particles |
| AU2005284835A1 (en) | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics Inc. | Imidazoquinoline compounds |
| CA2597587A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
| US8846697B2 (en) | 2006-05-31 | 2014-09-30 | The Regents Of The University Of California | Purine analogs |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| TW200911803A (en) | 2007-07-16 | 2009-03-16 | Organon Nv | 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| US8940725B2 (en) | 2010-05-31 | 2015-01-27 | Ono Pharmaceutical Co., Ltd. | Purinone derivative |
| AU2012255860C1 (en) | 2011-05-17 | 2015-12-10 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| MX2013013331A (es) | 2011-05-17 | 2014-10-17 | Principia Biopharma Inc | Derivados de azaindol como inhibidores de tirosina-cinasas. |
| US9073947B2 (en) | 2011-06-10 | 2015-07-07 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
| BR112014012727B1 (pt) | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| MA37711A1 (fr) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| CN104487441B (zh) | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
| SMT201900344T1 (it) | 2012-09-10 | 2019-07-11 | Principia Biopharma Inc | Composti di pirazolopirimidina come inibitori di chinasi |
| CN102942567B (zh) | 2012-11-09 | 2017-02-08 | 诸城市浩天药业有限公司 | 吡咯并喹啉醌的二钠盐结晶 |
| KR20150084923A (ko) | 2012-11-15 | 2015-07-22 | 파마시클릭스, 인코포레이티드 | 키나제 억제제로서의 피롤로피리미딘 화합물 |
| US20140142099A1 (en) | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| ME03000B (me) | 2012-12-21 | 2018-10-20 | Plexxikon Inc | Jedinjenja i metode modulacije kinaze i povezane indikacije |
| US9305578B1 (en) * | 2013-08-01 | 2016-04-05 | Seagate Technology Llc | Magnetic element with reduced shield-to-shield spacing |
| SG11201605417QA (en) | 2014-02-03 | 2016-08-30 | Cadila Healthcare Ltd | Heterocyclic compounds |
| CN107001362A (zh) | 2014-10-06 | 2017-08-01 | 默克专利有限公司 | 用作btk抑制剂的杂芳基化合物及其用途 |
| JP2016094368A (ja) | 2014-11-14 | 2016-05-26 | 大日本住友製薬株式会社 | ベンズイミダゾール化合物の新規結晶、及びその製造方法 |
| WO2016086358A1 (en) | 2014-12-02 | 2016-06-09 | Merck Sharp & Dohme Corp. | Hydroxymethyl piperidine orexin receptor antagonists |
| KR20170105021A (ko) | 2015-01-28 | 2017-09-18 | 아스테라스 세이야쿠 가부시키가이샤 | 피라진카르복사마이드 화합물의 제조 방법 및 그 합성 중간체 |
| EP3912979B1 (en) | 2015-06-03 | 2026-03-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN105753863B (zh) | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| US10358446B2 (en) | 2015-10-14 | 2019-07-23 | Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. | Bruton's tyrosine kinase inhibitors |
| KR102780243B1 (ko) | 2015-11-17 | 2025-03-14 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 다발성 경화증을 치료하는 방법 |
| EP3327134A1 (en) | 2016-11-28 | 2018-05-30 | Carsten Korth | Method and biomarkers for in vitro diagnosis of mental disorders |
| US20210113568A1 (en) | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
| CA3168146A1 (en) | 2020-01-20 | 2021-07-29 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms) |
| CN115867346B (zh) | 2020-06-02 | 2025-03-14 | Gb005股份有限公司 | 激酶抑制剂 |
| WO2022081512A1 (en) | 2020-10-12 | 2022-04-21 | Synubi Pharmaceuticals Llc | Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors |
| CA3201936A1 (en) | 2020-12-10 | 2022-06-16 | Minhua Chen | Crystal form of tolebrutinib and preparation method thereof |
| IL303834A (en) | 2020-12-23 | 2023-08-01 | Genzyme Corp | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts |
| CN117295735B (zh) | 2021-04-23 | 2026-05-12 | 杭州领业医药科技有限公司 | Tolebrutinib晶型、无定型及其制备方法和用途 |
| CN117412749A (zh) | 2021-05-21 | 2024-01-16 | 杭州领业医药科技有限公司 | Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途 |
| WO2022257845A1 (zh) | 2021-06-11 | 2022-12-15 | 苏州科睿思制药有限公司 | Tolebrutinib的晶型及其制备方法和用途 |
| IL310975A (en) | 2021-09-03 | 2024-04-01 | Novartis Ag | LOU064 for the treatment of multiple sclerosis |
| CA3241687A1 (en) | 2021-12-21 | 2023-06-29 | Tim Owens | Crystalline forms of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one and salts thereof |
| CN119212708A (zh) | 2022-05-13 | 2024-12-27 | 普林斯匹亚生物制药公司 | 用于髓鞘少突胶质细胞糖蛋白抗体疾病(mogad)的治疗性酪氨酸激酶抑制剂 |
| EP4540229A1 (en) | 2022-06-14 | 2025-04-23 | Principia Biopharma Inc. | Methods of making tolebrutinib |
| US20260022123A1 (en) | 2022-06-22 | 2026-01-22 | Principia Biopharma Inc. | Methods of Making Modified BTK Inhibitors |
| CA3260159A1 (en) | 2022-06-30 | 2024-01-04 | Principia Biopharma Inc. | Therapeutic Tyrosine Kinase Inhibitors for the Treatment of Multiple Sclerosis and Myasthenia Gravis |
| US20240173313A1 (en) | 2022-10-11 | 2024-05-30 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for multiple sclerosis |
| US20240238267A1 (en) | 2022-12-20 | 2024-07-18 | Genzyme Corporation | Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one |
| AU2024214470A1 (en) | 2023-02-01 | 2025-09-11 | Principia Biopharma Inc. | Methods of diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid |
| US20250282777A1 (en) | 2024-03-06 | 2025-09-11 | Principia Biopharma Inc. | Methods of Making Tolebrutinib |
| WO2026050513A1 (en) | 2024-08-30 | 2026-03-05 | Principia Biopharma Inc. | Tolebrutinib for multiple sclerosis |
| US20260060974A1 (en) | 2024-08-30 | 2026-03-05 | Principia Biopharma Inc. | Therapeutic tyrosine kinase inhibitors for multiple sclerosis |
-
2021
- 2021-12-22 IL IL303834A patent/IL303834A/en unknown
- 2021-12-22 MX MX2023007641A patent/MX2023007641A/es unknown
- 2021-12-22 EP EP21844903.1A patent/EP4267572A1/en active Pending
- 2021-12-22 JP JP2023537962A patent/JP2024501247A/ja active Pending
- 2021-12-22 WO PCT/US2021/064800 patent/WO2022140511A1/en not_active Ceased
- 2021-12-22 CN CN202180085786.XA patent/CN116710452B/zh active Active
- 2021-12-22 TW TW110148094A patent/TW202241887A/zh unknown
- 2021-12-22 AU AU2021409575A patent/AU2021409575B2/en active Active
- 2021-12-22 CA CA3206176A patent/CA3206176A1/en active Pending
- 2021-12-22 KR KR1020237024852A patent/KR20230124663A/ko active Pending
- 2021-12-22 US US18/268,577 patent/US12624030B2/en active Active
-
2023
- 2023-07-17 CO CONC2023/0009491A patent/CO2023009491A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116710452A (zh) | 2023-09-05 |
| AU2021409575B2 (en) | 2026-06-04 |
| AU2021409575A1 (en) | 2023-08-10 |
| US20240051955A1 (en) | 2024-02-15 |
| KR20230124663A (ko) | 2023-08-25 |
| US12624030B2 (en) | 2026-05-12 |
| EP4267572A1 (en) | 2023-11-01 |
| CN116710452B (zh) | 2026-06-05 |
| IL303834A (en) | 2023-08-01 |
| CO2023009491A2 (es) | 2023-07-31 |
| WO2022140511A1 (en) | 2022-06-30 |
| JP2024501247A (ja) | 2024-01-11 |
| TW202241887A (zh) | 2022-11-01 |
| CA3206176A1 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202108263B (en) | Imidazolonylquinoline compounds and therapeutic uses thereof | |
| TN2012000265A1 (en) | Triazolopyridines | |
| CO2023009491A2 (es) | Derivados de 4–amino–3–(4–fenoxifenilo)–1,3–dihidro–2h–imidazo[4,5–c]piridin–2–ona y sales de los mismos | |
| MX2013001805A (es) | Derivados de 2-(arilamino)-3h-imidazo [4,5-b] piridina-6-carboxamida y su uso como inhibidores de mpges-1. | |
| GB201104267D0 (en) | Pyrrolopyridineamino derivatives | |
| PH12012501800A1 (en) | 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor | |
| NO20090171L (no) | Substituerte aminopyrazolpyridiner og salter derav, fremgangsmate for fremstilling av slike, og farmasoytiske preparater inneholdende slike | |
| MX377305B (es) | DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2. | |
| PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| MX2022000656A (es) | Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll. | |
| GEAP202215630A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| TN2018000078A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| BR112013001088A2 (pt) | "derivados substituídos como inibidores a quinase de imidazoquinolina" | |
| SG10201806565SA (en) | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | |
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| MX2013005486A (es) | Inhibidores de la replicacion del vih. | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| SI2041133T1 (sl) | Imidazo (1,2,a)piridin-2-karboksamidni derivati, njihova priprava in njihova uporaba v terapevtiki | |
| MX2013011854A (es) | Compuestos de pirazol[3,4-b]piridina tri- y tetraciclica como agentes antineoplasicos. | |
| WO2018209363A3 (en) | PROPIONIC ACID DERIVATIVES AND ASSOCIATED METHODS OF USE | |
| MX2019010756A (es) | Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2). | |
| MX2016005759A (es) | Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| GEP20166481B (en) | (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors | |
| MX2022014168A (es) | Sal y formas de cristal de 4-amino-5-(6-(4-metilpiperazin-1-il)-ih benzo[d]imidazol-2-il)tieno[2,3-b]piridin-6(7h)-ona. |